Can systematic prostate biopsy be omitted in most men?
"It’s apparent that reducing overdiagnosis alone may not necessarily reduce over treatment, and that separate and specific focus on prevention of over treatment is still needed," Badar M. Mian, MD, writes.
MIPS 2020: How did urologists fare with quality program?
Almost all clinicians avoided negative fee schedule adjustment in 2022.
Wi-Fi exposure found to negatively impact sperm quality
Investigators found that mitigation methods such as adding a physical barrier or increasing distance could lessen the harmful effects.
How to bill Principal Care Management codes when 2 specialists are involved
"PCM codes require the practitioner to develop a disease-specific care plan, to obtain a patient’s verbal or written consent, and to educate the patient on PCM," write Jonathan Rubenstein, MD, and Mark Painter.
What do you think about a recent trend noting a growing number of patients calling physicians by their first names?
"In the office, absolutely, I should be called by my profession," says one urologist.
Combo of oncolytic immunotherapy and pembrolizumab continues to show promise in BCG-unresponsive NMIBC
“There is a critical unmet need for efficacious bladder-sparing therapies for patients with BCG-unresponsive bladder cancer,” said Roger Li, MD.
Dr. Alicia Morgans details decision between doublets and triplets in mCSPC
ADT intensification through doublet and triplet regimens has become standard for most patients with metastatic castration-sensitive prostate cancer, Alicia Morgans, MD, MPH, explained in a presentation at the 2022 LUGPA Annual Meeting.
Kidney cancer imaging agent TLX250-CDx succeeds in phase 3 trial
The co-primary end points have been achieved in the phase 3 ZIRCON trial exploring the novel PET imaging radiopharmaceutical TLX250-CDx in clear cell renal cell carcinoma.
Trial of novel imaging agent 64Cu SAR-Bombesin in prostate cancer hits enrollment milestone
64Cu SAR-Bombesin targets the Gastrin Releasing Peptide receptor, which is found on prostate tumors as well as several other tumors.
Post-transperineal biopsy pain appears manageable for patients
John Myrga, MD, discusses recent findings on levels of pain, anxiety, and embarrassment for patients undergoing a prostate biopsy with a transperineal approach versus a transrectal approach.
FDA updates label for mitomycin gel in UTUC
The FDA has updated the label for mitomycin-containing reverse thermal gel (Jelmyto) in low-grade upper-tract urothelial cancer by extending the in-use period for pyelocalyceal solution admixture.
2 Clarke Drive Cranbury, NJ 08512